Global Information
회사소개 | 문의

흑색종 : 파이프라인 리뷰

Melanoma - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 06월 상품 코드 232839
페이지 정보 영문 2011 Pages
가격
US $ 2,500 ₩ 2,851,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,702,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,553,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


흑색종 : 파이프라인 리뷰 Melanoma - Pipeline Review, H1 2018
발행일 : 2018년 06월 페이지 정보 : 영문 2011 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

흑색종은 멜라닌 세포가 악성 전환된 결과 발달한 종양입니다. 이러한 세포는 신경제방에서 파생된 것이며, 흑색종은 보통 피부에 나타나지만, 신경제방이 이동(유주)한 장소, 예를 들면 소화관이나 뇌에도 발생하는 경우가 있습니다. 남성보다 여성에게 잘 발병하며, 특히 여성의 다리나 남성의 등에 발생하는 경우가 많습니다. 피부상 점, 통증이 느껴지는 부위, 덩어리, 상처, 모양 등이 눈에 띄게 보이거나 느껴지는 것은 흑색종의 징후입니다. 치료법에는 수술, 방사선 치료, 양자선 치료가 있습니다.

흑색종(Melanoma) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업이나 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 최신 뉴스 및 발표와 함께 전해드립니다.

1. 서론

  • 흑색종 개요

2. 치료제 개발

3. 기업에서 개발중인 치료제

4. 대학/기관에서 연구중인 치료제

5. 파이프라인 제품 개요

6. 기업에서 개발중인 제품

7. 대학/기관에서 연구중인 제품

8. 치료제 개발에 종사하고 있는 기업

9. 치료제 평가

10. 치료제 개요

11. 최근의 파이프라인 동향

12. 휴지 상태인 프로젝트

13. 개발이 중지된 제품

14. 제품 개발 마일스톤

15. 부록

16. 도표

LSH 15.08.20

List of Tables

  • Number of Products under Development for Melanoma, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Melanoma - Pipeline by 4D Pharma PLC, H1 2018
  • Melanoma - Pipeline by 4P-Pharma SAS, H1 2018
  • Melanoma - Pipeline by 4SC AG, H1 2018
  • Melanoma - Pipeline by AB Science SA, H1 2018
  • Melanoma - Pipeline by AbbVie Inc, H1 2018
  • Melanoma - Pipeline by Abivax SA, H1 2018
  • Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
  • Melanoma - Pipeline by Aduro BioTech Inc, H1 2018
  • Melanoma - Pipeline by Advenchen Laboratories LLC, H1 2018
  • Melanoma - Pipeline by Aeglea BioTherapeutics Inc, H1 2018
  • Melanoma - Pipeline by Affichem SA, H1 2018
  • Melanoma - Pipeline by AGV Discovery SAS, H1 2018
  • Melanoma - Pipeline by AIMM Therapeutics BV, H1 2018
  • Melanoma - Pipeline by Alkermes Plc, H1 2018
  • Melanoma - Pipeline by Allergy Therapeutics Plc, H1 2018
  • Melanoma - Pipeline by Alligator Bioscience AB, H1 2018
  • Melanoma - Pipeline by Altor BioScience Corp, H1 2018
  • Melanoma - Pipeline by Amgen Inc, H1 2018
  • Melanoma - Pipeline by Angimmune LLC, H1 2018
  • Melanoma - Pipeline by Antibe Therapeutics Inc, H1 2018
  • Melanoma - Pipeline by Antigen Express Inc, H1 2018
  • Melanoma - Pipeline by APEIRON Biologics AG, H1 2018
  • Melanoma - Pipeline by Apexigen Inc, H1 2018
  • Melanoma - Pipeline by Aphios Corp, H1 2018
  • Melanoma - Pipeline by Aposense Ltd, H1 2018
  • Melanoma - Pipeline by Aprea AB, H1 2018
  • Melanoma - Pipeline by Aptose Biosciences Inc, H1 2018
  • Melanoma - Pipeline by Arcus Biosciences Inc, H1 2018
  • Melanoma - Pipeline by ARMO Biosciences Inc, H1 2018
  • Melanoma - Pipeline by Array BioPharma Inc, H1 2018
  • Melanoma - Pipeline by Asana BioSciences LLC, H1 2018
  • Melanoma - Pipeline by Astex Pharmaceuticals Inc, H1 2018
  • Melanoma - Pipeline by Atreca Inc, H1 2018
  • Melanoma - Pipeline by aTyr Pharma Inc, H1 2018
  • Melanoma - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
  • Melanoma - Pipeline by Autolus Ltd, H1 2018
  • Melanoma - Pipeline by Basilea Pharmaceutica Ltd, H1 2018
  • Melanoma - Pipeline by Batu Biologics Inc, H1 2018
  • Melanoma - Pipeline by Bayer AG, H1 2018
  • Melanoma - Pipeline by BeiGene Ltd, H1 2018
  • Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2018
  • Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018
  • Melanoma - Pipeline by BerGenBio ASA, H1 2018
  • Melanoma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
  • Melanoma - Pipeline by Biocad, H1 2018
  • Melanoma - Pipeline by Biogazelle NV, H1 2018
  • Melanoma - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018
  • Melanoma - Pipeline by BioLineRx Ltd, H1 2018
  • Melanoma - Pipeline by Bionomics Ltd, H1 2018
  • Melanoma - Pipeline by BioNTech AG, H1 2018
  • Melanoma - Pipeline by Biothera Pharmaceutical Inc, H1 2018
  • Melanoma - Pipeline by Biovista Inc, H1 2018
  • Melanoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Melanoma - Pipeline by Boston Biomedical Inc, H1 2018
  • Melanoma - Pipeline by BrightPath Biotherapeutics Co Ltd, H1 2018
  • Melanoma - Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Melanoma - Pipeline by Calithera Biosciences Inc, H1 2018
  • Melanoma - Pipeline by Can-Fite BioPharma Ltd, H1 2018
  • Melanoma - Pipeline by CBT Pharmaceuticals Inc, H1 2018
  • Melanoma - Pipeline by CCRP Therapeutics GmbH, H1 2018
  • Melanoma - Pipeline by Celgene Corp, H1 2018
  • Melanoma - Pipeline by Celldex Therapeutics Inc, H1 2018
  • Melanoma - Pipeline by Cellestia Biotech AG, H1 2018

List of Figures

  • Number of Products under Development for Melanoma, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H1 2018, provides an overview of the Melanoma (Oncology) pipeline landscape.

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 19, 116, 125, 1, 9, 217, 30 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 18, 13, 1, 73 and 10 molecules, respectively.

Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Melanoma - Overview
  • Melanoma - Therapeutics Development
  • Melanoma - Therapeutics Assessment
  • Melanoma - Companies Involved in Therapeutics Development
  • Melanoma - Drug Profiles
  • Melanoma - Dormant Projects
  • Melanoma - Discontinued Products
  • Melanoma - Product Development Milestones
  • Appendix
Back to Top
전화 문의
이용안내
 
BCC Research